Hong Kong Healthtech Stock News

Why InnoCare Pharma Stock Is In Focus After EHA 2026 InnoCare Pharma (SEHK:9969) has drawn fresh attention after presenting data from more than 40 clinical studies of its BTK inhibitor orelabrutinib at the European Hematology Association 2026 Congress. The company highlighted outcomes across several hematological cancers, including chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, mantle cell lymphoma, diffuse large B cell lymphoma, and primary central nervous...

Melbourne Enterprises Limited ( HKG:158 ) is about to trade ex-dividend in the next 3 days. Typically, the ex-dividend...

Shareholders might have noticed that HKR International Limited ( HKG:480 ) filed its full-year result this time last...

Precision Tsugami (China) (SEHK:1651) is back in focus after coverage highlighting its wide discount to estimated fair value, as the board prepares to approve annual results and consider a potential final dividend. See our latest analysis for Precision Tsugami (China). The recent focus on valuation comes after a powerful run in Precision Tsugami (China)'s stock, with a 93.8% 90 day share price return and a very large 3 year total shareholder return that points to strong long term compounding...

Shanghai Henlius Biotech (SEHK:2696) has just cleared two regulatory hurdles that matter for investors, with GMP approval for HANBEIYOU production in China and a new gastric cancer indication for its HANSIZHUANG immunotherapy. See our latest analysis for Shanghai Henlius Biotech. These regulatory approvals arrive after a mixed stretch for Shanghai Henlius Biotech’s stock, with the share price up 7.51% year to date but down 11.45% over the past month. The 1-year total shareholder return of...

Earlier in June 2026, RemeGen announced that China’s National Medical Products Administration granted full approval for telitacicept in Sjögren’s disease and conditional approval in IgA nephropathy, both supported by positive Phase 2 and Phase 3 clinical data. These decisions expand telitacicept to five approved autoimmune indications in China, underscoring the clinical breadth of RemeGen’s first-in-class BLyS/APRIL dual-target biologic. We’ll now examine how this broadened telitacicept...

Shareholders of Greater Bay Area AI Computing Tech (SEHK:1396) recently approved all resolutions at the annual general meeting, including mandates to issue and repurchase shares, giving the company added flexibility around its AI computing focused plans. See our latest analysis for Greater Bay Area AI Computing Tech. Greater Bay Area AI Computing Tech’s recent AGM approval comes after a sharp 90 day share price return of 111.46% and a year to date share price return of 146.23%, while the 1...

Why the EMA inspection matters for WuXi Biologics (Cayman) The latest move in WuXi Biologics (Cayman) (SEHK:2269) stock comes after its Suzhou Biosafety Testing Center passed a four day European Medicines Agency GMP inspection with zero critical findings, backing 19 EU biologics applications. For investors, this clean outcome highlights that a key part of WuXi Biologics (Cayman)'s testing and quality control operations aligns with European regulatory expectations, which can be important when...

In June 2026, J&T Global Express Limited was added to the Hang Seng Index and closed a private placement with SF Holdings Group, Inc. as an investor. This combination of index inclusion and backing from a major logistics peer underscores J&T’s growing relevance within the regional express delivery ecosystem. Now we’ll explore how Hang Seng Index inclusion might influence J&T Global Express’s investment narrative and its longer-term positioning. The best AI stocks today may lie beyond giants...

China Medical System Holdings (SEHK:867) drew fresh attention after presenting preclinical data for its INHBE-targeting siRNA drug CMS-D008 at the American Diabetes Association’s 86th Scientific Sessions, highlighting weight loss and muscle preservation in animal models. See our latest analysis for China Medical System Holdings. Despite the CMS-D008 update, China Medical System Holdings’ share price has eased, with a 30-day share price return down 6.73% and a 90-day share price return down...

Frost & Sullivan’s 2026 AI Infrastructure Orchestration Platform White Paper recently named Phancy Group’s Rise vGPU a Tier 1 Leading Platform and ranked its ModelHub offering highest among model management platforms, citing strengths in handling heterogeneous AI infrastructure and improving GPU utilization. This independent recognition underscores Phancy Group’s role in pushing China’s AI ecosystem toward a “compute orchestration” era rather than sheer compute accumulation, highlighting the...

XtalPi Holdings (SEHK:2228) has drawn fresh investor attention after announcing a new R&D alliance with a global biopharmaceutical partner to co-develop an oral small molecule therapy targeting a complex GPCR receptor. See our latest analysis for XtalPi Holdings. XtalPi Holdings' recent R&D alliance arrives after a weak run in the share price, with the 30 day share price return down 16.33% and the year to date share price return down 33.83%, even as the 1 year total shareholder return is...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Fresh U.S. tariff proposals of up to 12.5% on imports from 60 economies are reshaping the risk profile for globally exposed stocks, especially those tied to complex cross border supply chains. With partial exemptions for electronics and AI related products, some areas may find a softer landing while others face higher costs and potential pressure on margins. This article focuses on three stocks that appear negatively exposed to the latest trade policy headlines and explains how these tariff...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

It looks like TCL Electronics Holdings Limited ( HKG:1070 ) is about to go ex-dividend in the next 4 days. The...

Get Nice Holdings (SEHK:64) has reported fresh numbers for FY 2026, with first half revenue of HK$161.1 million and basic EPS of HK$0.08, alongside trailing twelve month revenue of HK$222.2 million and EPS of HK$0.09, against a current share price of HK$3.31. Over recent periods the company has seen revenue move from HK$214.6 million in the first half of FY 2025 to HK$220.7 million in the second half, while EPS shifted from HK$0.07 to HK$0.02. This sets the backdrop for the latest figures and...

BYD (SEHK:1211) has received over 150,000 pre orders for its new flagship Great Tang electric SUV. The company is preparing to launch the Great Tang in Europe alongside increased investment in European manufacturing and R&D. These moves raise questions about BYD's ability to scale production and support overseas growth while meeting international demand. BYD enters this phase with its share price at HK$80.85, after the stock declined 6.6% over the past week and 10.4% over the past month...

RemeGen (SEHK:9995) is back in focus after China’s National Medical Products Administration approved new indications for its autoimmune drug Telitacicept in Sjögren’s disease and conditionally in IgA nephropathy, expanding its treated patient pools. See our latest analysis for RemeGen. At a latest share price of HK$68.5, RemeGen’s 1 day share price return of 1.63% follows a 30 day share price decline of 19.32%. Its 1 year total shareholder return of 37.27% and 3 year total shareholder return...

A unit of Kingboard Holdings recently moved to raise about US$1.50 billion through a block trade of shares in Kingboard Laminates, adjusting its financing mix and ownership structure in the process. This fundraising comes as Kingboard Laminates benefits from very strong AI server demand for high-grade laminates and copper foil, where tight supply has turned into concrete order pressure. We will now examine how this large capital raise, set against constrained AI server material supply,...

CARsgen Therapeutics Holdings recently presented early clinical data at the 2026 European Hematology Association Congress showing its allogeneic CAR T-cell candidates CT0596 and CT1190B produced high response rates with manageable safety in heavily pretreated blood cancer patients. An interesting aspect for investors is that both products are off-the-shelf allogeneic CAR T therapies, with responses seen even in patients previously treated with CAR T or bispecific antibodies. We will now...

Akeso (SEHK:9926) is back in focus after presenting Phase II data for its anti CD47 antibody ligufalimab in acute myeloid leukemia at the 2026 European Hematology Association Congress, highlighting survival and response outcomes versus standard therapy. See our latest analysis for Akeso. Akeso's HK$87.55 share price has seen a 4.35% 1 day gain but is still down 22.38% over 30 days and 24.26% over 90 days. The 3 year total shareholder return of 152.67% contrasts with a 4.89% decline over the...

In recent weeks, global markets have shown mixed performances, with the U.S. indices like the Nasdaq Composite and Russell 2000 posting gains amid geopolitical developments and steady interest rates from the Federal Reserve. As investors navigate this environment of cautious optimism and potential rate hikes, small-cap stocks present intriguing opportunities due to their growth potential and often overlooked value. In this context, identifying stocks with strong fundamentals and insider...

Hong Kong is preparing to launch trading of Chinese treasury futures in offshore yuan on August 3, 2026, opening another channel for investors who care about currency risk, fixed income exposure, and deeper access to China’s markets. As yuan denominated products expand and hedging tools improve, some Hong Kong financial stocks could see stronger trading flows or more client demand, while others may see little direct benefit. This article walks through three Hong Kong Financials and Exchange...